Imeroprubart
Phase 2
Imeroprubart is one of 23 therapeutic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
26 competitors in Chronic Inflammatory Demyelinating Polyneuropathy
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Fabhalta
Johnson & JohnsonPhase 3
Igpro20
CSL BehringPhase 3
NPB-01
NNihon Pharmaceutical Co., Ltd
Phase 3
Ivig
ArgenxPhase 3
Vyvgart
ArgenxPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Igpro10
CSL BehringPhase 3
Immunoglobulin
SanofiPhase 2
Immunoglobulins
CSL BehringPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Imeroprubart. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- IImmunovant Sciences GmbH